Provided by Tiger Trade Technology Pte. Ltd.

Weight Loss Drugs

1,599.33
-27.9871-1.72%
Number of Gainers:1
Number of Losers:6
Number of Flat:- -
PE:- -
High:1,653.59
Open:1,625.82
Low:1,594.84
Close:1,627.31
Volume:75.96M
Turnover:7.45B
Market Cap:1.66T
Float Cap:1.60T

Loading ...

Eli Lilly: Plans to Initiate Phase 3 Studies of Eloratzp Co-Formulation Product by 2026 End Using Optimized Escalation Schedule

THOMSON REUTERS
·
Yesterday

Eli Lilly: at 48 Weeks, All Combinations of Eloratzp Met Primary & Secondary Endpoints

THOMSON REUTERS
·
Yesterday

Experimental Lilly Combination Drug Tops Zepbound in Weight-Loss Trial

Reuters
·
Yesterday

Eli Lilly: Participants Taking Eloratzp Lost up to Average of 54.1 Lbs (23.3%) VS. 34.4 Lbs (14.8%) with Tirzepatide 15 Mg

THOMSON REUTERS
·
Yesterday

Novo Nordisk announces new data on CagriSema

TIPRANKS
·
Yesterday

Lilly Says Phase 3b ADtouch Trial Shows Ebglyss Beats Placebo in Hand and Foot Atopic Dermatitis Skin Clearance at Week 16

Reuters
·
Yesterday

Eli Lilly - 77% of Ebglyss Patients Reported Satisfaction with Hand Clearance at Week 16

THOMSON REUTERS
·
Yesterday

Eli Lilly - Ebglyss Monotherapy Meets Primary and Secondary Endpoints at Week 16 in Phase 3B Adtouch Study

THOMSON REUTERS
·
Yesterday

New Phase 3B Data Show Lilly's Ebglyss (Lebrikizumab-Lbkz) Delivered Significant and Rapid Improvements in Skin Clearance, Itch, Pain, and Patient Satisfaction in People with Moderate-to-Severe Hand and Foot Atopic Dermatitis

THOMSON REUTERS
·
Yesterday

Eli Lilly - Treatment-Emergent Adverse Events in 41.8% Ebglyss Patients, 39.6% Placebo, All Mild or Moderate

THOMSON REUTERS
·
Yesterday

Eli Lilly - Submits Ebglyss Adtouch Data to FDA and Plans Global Regulatory Submissions for Label Update

THOMSON REUTERS
·
Yesterday

Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States

GlobeNewswire
·
Yesterday

Patients Switching to Novo Nordisk's Wegovy Pill from Shots Lose More Weight in Real-World Study

Reuters
·
Yesterday

Sino Biopharmaceutical Stock Rises 2.9% in Hong Kong

Dow Jones
·
Yesterday

Eli Lilly reports results from TRIUMPH-2 Phase 3 trial

TIPRANKS
·
Yesterday

Lilly's Experimental Drug Cuts Weight by 21% in Diabetes Trial

Reuters
·
Yesterday

Eli Lilly - Retatrutide 12 Mg Results in 49.6 Lb (20.8%) Weight Loss over 80 Weeks

THOMSON REUTERS
·
Yesterday

Lilly's Triple Agonist, Retatrutide, Delivered Substantial Weight Loss and A1c Reduction, Underscoring Its Potential Promise for People with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Yesterday

Eli Lilly - to Submit Biologics License Application for Retatrutide in Q1 2027

THOMSON REUTERS
·
Yesterday

Eli Lilly - 59.5% of Retatrutide 12 Mg Participants no Longer Meet Bmi Criteria for Obesity

THOMSON REUTERS
·
Yesterday